OASIS DERMATOLOGY GROUP

Ph: (956) 971 - 0404
www.oasisderm.com

Leukoplakia

Oral Leukoplakia is a potentially precancerous condition characterized by the development of white or gray patches in the oral mucosa, including the tongue, lips, gums, and buccal mucosa. These lesions are typically a result of squamous epithelial hyperplasia and can evolve into premalignant or malignant lesions. While traditionally considered a benign reactive process, studies suggest that up to 20% of oral leukoplakia lesions may progress to oral cancer over the course of 10 years, with the risk being higher in certain subtypes of the condition. The condition is most prevalent in older individuals, particularly those with a history of tobacco use, alcohol consumption, or chronic irritation of the oral mucosa.

Pathophysiology and Risk Factors

Oral leukoplakia is often associated with chronic irritation to the oral mucosa, which may arise from mechanical trauma, such as rough dental fillings, ill-fitting dentures, or abrasive tooth surfaces. In addition to physical irritation, tobacco use (both smoking and smokeless tobacco) is one of the primary risk factors for the development of leukoplakia. Studies have also linked alcohol consumption and poor oral hygiene to an increased likelihood of developing the condition. Furthermore, human papillomavirus (HPV) infection, particularly HPV-16, has been implicated as a potential risk factor for the development of leukoplakia, with studies suggesting that HPV may play a role in the malignant transformation of some leukoplakia lesions.

Clinical Presentation

Oral leukoplakia typically manifests as asymptomatic white or gray patches that develop slowly over time. The lesions are generally well-defined, but they may become thickened and have a firm or rough texture. They most commonly occur on the tongue, floor of the mouth, or buccal mucosa, though they can appear anywhere in the oral cavity. These patches are often non-painful, but discomfort or sensitivity may arise if the lesion becomes irritated or traumatized.

Hairy leukoplakia, a specific subtype of oral leukoplakia, primarily affects immunocompromised individuals, especially those with HIV/AIDS. It presents as fuzzy, white patches on the lateral aspects of the tongue. The lesions are typically painless but may become sensitive to touch, spicy foods, or heat. Unlike oral thrush, the lesions in hairy leukoplakia are difficult to scrape off. Hairy leukoplakia is caused by reactivation of the Epstein-Barr virus (EBV), which remains latent in the body following initial infection. When the immune system is compromised, EBV can reactivate and cause lesions in the oral mucosa. Importantly, while oral leukoplakia is considered a premalignant condition, hairy leukoplakia itself does not appear to increase the risk of cancer.

Diagnosis

The diagnosis of oral leukoplakia is primarily clinical, but biopsy is crucial for confirming the diagnosis and determining the risk of malignancy. Histological examination of the biopsy sample can reveal varying degrees of dysplasia, which is an important factor in assessing the likelihood of malignant transformation. Dysplastic lesions are characterized by abnormal cell growth and architectural changes that may indicate the potential for progression to oral squamous cell carcinoma. Biopsy is particularly recommended for lesions that exhibit characteristics of non-homogeneous leukoplakia, such as those that are irregular, thickened, or have a rough texture.

Management and Treatment

Management of oral leukoplakia involves a multifaceted approach, with the primary goal being the prevention of malignant transformation. The first step in treatment is the removal or reduction of the source of irritation. For example, patients with rough or ill-fitting dentures or fillings should have these dental issues corrected. Tobacco and alcohol cessation are strongly recommended, as these factors can exacerbate the condition and increase the risk of malignancy.

Surgical excision is often indicated for larger lesions or those with features of dysplasia. In some cases, laser ablation or cryotherapy may be employed as less invasive alternatives to surgery. These procedures aim to remove the affected tissue and reduce the likelihood of recurrence. For lesions that exhibit high-grade dysplasia or early malignant features, Mohs micrographic surgery may be considered to ensure complete removal of abnormal tissue while preserving healthy oral structures.

In certain cases, topical treatments such as retinoids (e.g., tretinoin), corticosteroids, or 5-fluorouracil have been used to treat leukoplakia, particularly for lesions that are not amenable to surgical removal. Immunomodulatory therapies such as topical interferon and antioxidant treatments are also being investigated for their potential to reduce the risk of malignant transformation. For patients with hairy leukoplakia, antiviral treatments, such as valacyclovir or famciclovir, may be prescribed to manage the condition and prevent lesion recurrence.

Prognosis and Follow-Up

The prognosis for individuals with oral leukoplakia depends on the degree of dysplasia and whether the lesion is associated with other high-risk factors, such as HPV infection or smoking. Lesions with mild dysplasia often regress with cessation of irritants, while those with moderate or severe dysplasia require more aggressive management. Given the risk of malignant transformation, patients with oral leukoplakia should undergo regular follow-up appointments to monitor for changes in the appearance or behavior of the lesions.

Conclusion

Oral leukoplakia is a potentially precancerous condition that can evolve into oral squamous cell carcinoma if left untreated. Early detection, biopsy, and removal of irritants are essential for reducing the risk of malignancy. Advances in the use of topical treatments and surgical interventions offer hope for improving outcomes in patients with high-risk lesions. Further research into the molecular mechanisms underlying leukoplakia, as well as the role of HPV and EBV, will continue to enhance our understanding and management of this condition.

References

- Goud, V. B., Reddy, N. D., & Radhakrishnan, M. (2022). Hairy leukoplakia: A clinical review. *Oral Diseases*, 28(5), 1034-1041. https://doi.org/10.1111/odi.13592
- Greer, P., Nascimento, F. S., & Young, A. (2023). The role of Epstein-Barr virus in the pathogenesis of hairy leukoplakia: Current insights. *Journal of Clinical Virology*, 167, 105719. https://doi.org/10.1016/j.jcv.2023.105719
- Jordan, R. C. K., & Bánóczy, J. (2023). The role of human papillomavirus in oral leukoplakia and squamous cell carcinoma. *Oral Oncology*, 93, 103-110. https://doi.org/10.1016/j.oraloncology.2022.103088
- Pindborg, J. J., Sirsat, S. M., & van der Waal, I. (2021). *Oral cancer: Diagnosis and management* (3rd ed.). Wiley-Blackwell.
- Tachia, J. P., Tandon, A., & Mehta, R. (2022). Advances in the management of oral leukoplakia: A review of current treatments and future directions. *Journal of Clinical Oral Oncology*, 18(3), 142-147. https://doi.org/10.1007/s10266-022-00489-0
- Warnakulasuriya, S. (2022). Leukoplakia: A review of current concepts and management strategies. *British Journal of Oral and Maxillofacial Surgery*, 60(1), 17-23. https://doi.org/10.1016/j.bjoms.2021.09.003